Printed from Voxsanity (voxsanity.com.au) — NCT06846671 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
AI generated eligibility summary.
Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source.
How we use AI
Who might be able to join this trial:
People who have been diagnosed with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) and whose condition currently needs treatment, based on recognised medical guidelines.
People who have previously been treated for CLL or SLL with two specific types of targeted therapy drugs (known as a BTK inhibitor and a BCL2 inhibitor).
People with SLL who have disease that can be measured and detected on a CT or MRI scan.
People whose general health and ability to carry out daily activities falls within an acceptable range, as measured by a standard medical scoring system (scores 0, 1, or 2 on the ECOG scale).
People whose liver is functioning adequately, based on test results.
People whose blood clotting function is adequate, based on test results.
Who may not be able to join:
People who have a related blood condition called prolymphocytic leukaemia, or who have had, or are suspected of having, a transformation of their CLL/SLL into a more aggressive form of lymphoma (called Richter's transformation).
People who have had a stem cell transplant using their own cells, or a type of immune cell therapy (CAR-T cell therapy), within the last 3 months.
People whose cancer has spread to the central nervous system (brain or spinal cord).
People who have previously been treated with a specific type of drug known as a BTK protein degrader.
People who currently have a serious fungal, bacterial, or viral infection that requires intravenous or injected medication to treat.
People who have significant heart or blood vessel disease.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 9 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.
Contact this trial
Principal Investigator: Study Director, BeOne Medicines
Concord Repatriation General Hospital, Concord, New South Wales
Gosford Hospital, Gosford, New South Wales
Port Macquarie Base Hospital, Port Macquarie, New South Wales
Prince of Wales Hospital, Randwick, New South Wales
Toowoomba Hospital, Toowoomba, Queensland
Flinders Medical Centre, Bedford PK, South Australia
The Alfred Hospital, Melbourne, Victoria
Perth Blood Institute, West Perth, Western Australia
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Voxsanity
Clinical trials and treatments, explained plainly · voxsanity.com.au
Date:
To: My Doctor
Re: Clinical trial enquiry
I am writing to enquire about the following clinical trial which may be relevant to my care:
Trial: NCT06846671
Sponsor: BeOne Medicines
Phase: Phase 3
Status: Recruiting
Condition: Leukaemia
Trial contact: 1.877.828.5568
More information: https://clinicaltrials.gov/study/NCT06846671
Eligibility summary (AI generated)
Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.
Who might be able to join this trial:
People who have been diagnosed with chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) and whose condition currently needs treatment, based on recognised medical guidelines.
People who have previously been treated for CLL or SLL with two specific types of targeted therapy drugs (known as a BTK inhibitor and a BCL2 inhibitor).
People with SLL who have disease that can be measured and detected on a CT or MRI scan.
People whose general health and ability to carry out daily activities falls within an acceptable range, as measured by a standard medical scoring system (scores 0, 1, or 2 on the ECOG scale).
People whose liver is functioning adequately, based on test results.
People whose blood clotting function is adequate, based on test results.
Who may not be able to join:
People who have a related blood condition called prolymphocytic leukaemia, or who have had, or are suspected of having, a transformation of their CLL/SLL into a more aggressive form of lymphoma (called Richter's transformation).
People who have had a stem cell transplant using their own cells, or a type of immune cell therapy (CAR-T cell therapy), within the last 3 months.
People whose cancer has spread to the central nervous system (brain or spinal cord).
People who have previously been treated with a specific type of drug known as a BTK protein degrader.
People who currently have a serious fungal, bacterial, or viral infection that requires intravenous or injected medication to treat.
People who have significant heart or blood vessel disease.
Important: Always verify eligibility with the trial site directly before applying.
Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.
This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 9 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.
Trial details
Status
Recruiting
Phase
Phase 3
Sponsor
BeOne Medicines
Registry
ClinicalTrials.gov
Start date
10 April 2025
Est. completion
15 May 2028
Where this trial is recruiting
🇦🇷 Argentina
🇦🇺 Australia
🇧🇷 Brazil
🇨🇦 Canada
🇨🇿 Czechia
🇩🇪 Germany
🇮🇹 Italy
🇯🇵 Japan
🇳🇱 Netherlands
🇵🇱 Poland
🇰🇷 South Korea
Turkey (Türkiye)
🇬🇧 United Kingdom
🇺🇸 United States
8 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Progression-Free Survival (PFS) by Independent Review Committee (IRC)
Can't join this trial?
Expanded access pathways
If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.
Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.